Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome (2022)
- Authors:
- USP affiliated authors: SILVA, CLOVIS ARTUR ALMEIDA DA - FM ; KUPA, LEONARD DE VINCI KANDA - FM ; BORBA NETO, EDUARDO FERREIRA - FM ; BONFA, ELOISA SILVA DUTRA DE OLIVEIRA - FM
- Unidade: FM
- DOI: 10.1177/09612033221102073
- Subjects: COVID-19; ANTICORPOS ANTIFOSFOLIPÍDEOS; IMUNOGENÉTICA; FATORES DE RISCO; COAGULAÇÃO SANGUÍNEA
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Status:
- Artigo possui versão em acesso aberto em repositório (Green Open Access)
- Versão do Documento:
- Versão submetida (Pré-print)
- Acessar versão aberta:
-
ABNT
SIGNORELLI, Flavio et al. Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome. Lupus, v. 31, n. 8, p. 974-984, 2022Tradução . . Disponível em: https://doi.org/10.1177/09612033221102073. Acesso em: 02 abr. 2026. -
APA
Signorelli, F., Balbi, G. G. M., Aikawa, N. E., Silva, C. A. A. da, Kupa, L. de V. K., Medeiros-Ribeiro, A. C., et al. (2022). Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome. Lupus, 31( 8), 974-984. doi:10.1177/09612033221102073 -
NLM
Signorelli F, Balbi GGM, Aikawa NE, Silva CAA da, Kupa L de VK, Medeiros-Ribeiro AC, Yuki EFN, Pasoto SG, Saad CGS, Borba Neto EF, Bonfa ESD de O. Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome [Internet]. Lupus. 2022 ; 31( 8): 974-984.[citado 2026 abr. 02 ] Available from: https://doi.org/10.1177/09612033221102073 -
Vancouver
Signorelli F, Balbi GGM, Aikawa NE, Silva CAA da, Kupa L de VK, Medeiros-Ribeiro AC, Yuki EFN, Pasoto SG, Saad CGS, Borba Neto EF, Bonfa ESD de O. Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome [Internet]. Lupus. 2022 ; 31( 8): 974-984.[citado 2026 abr. 02 ] Available from: https://doi.org/10.1177/09612033221102073 - Thalidomide measurement in plasma and dried plasma spot by SPE combined with UHPLC-MS/MS for therapeutic drug monitoring
- SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy
- Impact of distinct therapies on antibody response to SARS-CoV-2 vaccine in systemic lupus erythematosus
- Short-term Accrual 2019 European League Against Rheumatism/American College of Rheumatology Domains and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage in Lupus Patients With and Without Nephritis at Disease Onset
- First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR)
- 2019-EULAR/ACR classification criteria domains at diagnosis: predictive factors of long-term damage in systemic lupus erythematosus
- Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial
- Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2
- Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis
- Complete urological evaluation including sperm DNA fragmentation in male systemic lupus erythematosus patients
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
